Lorlatinib and its Impurities

Lorlatinib is approved in the US and in Europe for the second- or third-line treatment of ALK-positive metastatic non-small-cell lung cancer (NSCLC). Reference standards of Lorlatinib API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.

Displaying 3 results for Lorlatinib Impurities
PA 12 1490000

Lorlatinib

Lorlatinib


  • Catalogue No.:PA 12 1490000

  • CAS :

    1454846-35-5

  • Molecular Formula : C21H19FN6O2

  • Molecular Weight : 406.42

PA 12 1491000

(S)-Lorlatinib

(S)-Lorlatinib


  • Catalogue No.:PA 12 1491000

  • CAS :

    1454847-76-7

  • Molecular Formula : C21H19FN6O2

  • Molecular Weight : 406.42

PA 12 1491001

3-(4-Fluorophenyl)-1-methyl-N-((1-methyl-3-(pyridin-2-yl)-1H-pyrazol-5-yl)methyl)-1H-pyrazole-5-carboxamide

3-(4-Fluorophenyl)-1-methyl-N-((1-methyl-3-(pyridin-2-yl)-1H-pyrazol-5-yl)methyl)-1H-pyrazole-5-carboxamide


  • Catalogue No.:PA 12 1491001

  • CAS :

    2320467-06-7

  • Molecular Formula : C21H19FN6O

  • Molecular Weight : 390.42

CPHI INDIA- 28, 30 November